Peptide library / Hormones & metabolism / Tesamorelin
Tesamorelin
A growth hormone-releasing hormone analog approved to reduce belly fat in people with HIV.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Reduce excess abdominal fat in HIV lipodystrophyFDA approved
- Liver fat reductionSmall human studies
How it is thought to work
Tesamorelin stimulates the pituitary gland to release growth hormone, which reduces fat around the abdominal organs.
What the evidence shows
Pivotal trials showed a reduction in visceral fat compared with placebo. The effect fades when treatment stops.
Safety and unknowns
Joint pain, fluid retention and raised blood sugar can occur.
Regulatory status
FDA-approved as Egrifta in 2010 for HIV-associated lipodystrophy only.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Hormones & metabolism
Triptorelin
FDA-approvedA GnRH agonist used for prostate cancer and central precocious puberty.
Vasopressin
FDA-approvedA nine amino acid hormone used to raise blood pressure in vasodilatory shock.
Somatropin
FDA-approvedRecombinant human growth hormone, a 191 amino acid protein used for growth failure and deficiency.
General information, not medical advice. Do not buy or inject unregulated peptides.